Movement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test

Market Focus05-21 00:16

On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the company's Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer.

The newly approved test integrates genomic and epigenomic profiling from a single blood draw and offers higher sensitivity to detect circulating tumor DNA. Notably, the Guardant360 Liquid CDx can assess a 100-times wider genomic footprint than the previously approved Guardant360 CDx, with results delivered within seven days. The approval marks a significant expansion of the company's precision oncology platform and strengthens its competitive position in the liquid biopsy market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188757147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 00:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188757147","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test","media":"Market Focus","content":"<p><p>On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the company's Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer.</p><p>The newly approved test integrates genomic and epigenomic profiling from a single blood draw and offers higher sensitivity to detect circulating tumor DNA. Notably, the Guardant360 Liquid CDx can assess a 100-times wider genomic footprint than the previously approved Guardant360 CDx, with results delivered within seven days. The approval marks a significant expansion of the company's precision oncology platform and strengthens its competitive position in the liquid biopsy market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 00:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the company's Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer.</p><p>The newly approved test integrates genomic and epigenomic profiling from a single blood draw and offers higher sensitivity to detect circulating tumor DNA. Notably, the Guardant360 Liquid CDx can assess a 100-times wider genomic footprint than the previously approved Guardant360 CDx, with results delivered within seven days. The approval marks a significant expansion of the company's precision oncology platform and strengthens its competitive position in the liquid biopsy market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1188757147","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188757147","pubTimestamp":1779293777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动静提示|Guardant Health常规交易涨10.09%FDA批准下一代液体活检测试","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the company's Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer.The newly approved test integrates genomic and epigenomic profiling from a single blood draw and offers higher sensitivity to detect circulating tumor DNA. Notably, the Guardant360 Liquid CDx can assess a 100-times wider genomic footprint than the previously approved Guardant360 CDx, with results delivered within seven days. The approval marks a significant expansion of the company's precision oncology platform and strengthens its competitive position in the liquid biopsy market.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188757147","isCrawlerRequest":true}